113 related articles for article (PubMed ID: 3683172)
1. Detection of malignant tumors: water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.
Dowd TL; Kaplan BA; Gupta RK; Aisen P
Magn Reson Med; 1987 Oct; 5(4):395-7. PubMed ID: 3683172
[TBL] [Abstract][Full Text] [Related]
2. Assessment of proton nuclear magnetic resonance spectroscopy for detection of malignancy.
Wilding P; Senior MB; Inubushi T; Ludwick ML
Clin Chem; 1988 Mar; 34(3):505-11. PubMed ID: 3349601
[TBL] [Abstract][Full Text] [Related]
3. Detection of tumours with nuclear magnetic resonance spectroscopy of plasma.
Berger S; Pflüger KH; Etzel WA; Fischer J
Eur J Cancer Clin Oncol; 1989 Mar; 25(3):535-43. PubMed ID: 2703007
[TBL] [Abstract][Full Text] [Related]
4. [H-NMR spectroscopy of plasma cannot be used for cancer screening].
Tran Dinh S; Schlumberger M; Gicquel C; Neumann JM; Hervé M; Turpin G; Parmentier C
Bull Cancer; 1988; 75(8):795-800. PubMed ID: 3179513
[TBL] [Abstract][Full Text] [Related]
5. Proton nuclear magnetic resonance methyl and methylene linewidths from plasma decrease during postprandial lipemia.
Verdery RB; Benham DF; McLennan I; Busby MJ; Wehrle JP; Glickson JD
Biochim Biophys Acta; 1989 Dec; 1006(3):287-90. PubMed ID: 2597673
[TBL] [Abstract][Full Text] [Related]
6. Assessing the value of identifying the presence of malignant disease in human plasma by proton nuclear magnetic resonance spectroscopy.
Buchthal SD; Hardy MA; Brown TR
Am J Med; 1988 Oct; 85(4):528-32. PubMed ID: 3177400
[TBL] [Abstract][Full Text] [Related]
7. Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors.
Okunieff P; Zietman A; Kahn J; Singer S; Neuringer LJ; Levine RA; Evans FE
N Engl J Med; 1990 Apr; 322(14):953-8. PubMed ID: 2314447
[TBL] [Abstract][Full Text] [Related]
8. Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma.
Fossel ET; Carr JM; McDonagh J
N Engl J Med; 1986 Nov; 315(22):1369-76. PubMed ID: 3022146
[TBL] [Abstract][Full Text] [Related]
9. Proton nuclear magnetic resonance spectroscopy of plasma lipoproteins in malignancy.
Nabholtz JM; Rossignol A; Farnier M; Gambert P; Tremeaux JC; Friedman S; Guerrin J
Acta Oncol; 1988; 27(5):479-82. PubMed ID: 3203006
[TBL] [Abstract][Full Text] [Related]
10. [Prostatic tumors. Detection by proton nuclear magnetic resonance spectroscopy of plasma lipoproteins].
Nabholtz JM; Tremeaux JC; Rossignol A; Farnier M; Gambert P; Briet S; Guerrin J
J Urol (Paris); 1989; 95(4):209-12. PubMed ID: 2477463
[TBL] [Abstract][Full Text] [Related]
11. Relationships between the proton nuclear magnetic resonance properties of plasma lipoproteins and cancer.
Otvos JD; Jeyarajah EJ; Hayes LW; Freedman DS; Janjan NA; Anderson T
Clin Chem; 1991 Mar; 37(3):369-76. PubMed ID: 2004443
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral contraception on water-suppressed proton NMR spectra of plasma.
Carlier PG; Vaesen F; Gilles RG; Fradin EA; Rorive GL
Magn Reson Med; 1991 Jan; 17(1):269-73. PubMed ID: 1648654
[TBL] [Abstract][Full Text] [Related]
13. An improved method for the detection of malignancy by proton NMR spectroscopy of plasma.
Otvos JD; Coffer MC; Chen SM; Wehrli S
Biochem Biophys Res Commun; 1987 Jun; 145(3):1397-403. PubMed ID: 3606609
[TBL] [Abstract][Full Text] [Related]
14. The proton NMR of blood plasma and the test for cancer.
Herring FG; Phillips PS; Pritchard H; Silver H; Whittal KP
Magn Reson Med; 1990 Oct; 16(1):35-48. PubMed ID: 2175009
[TBL] [Abstract][Full Text] [Related]
15. Alteration of aliphatic lipid proton NMR linewidths by malignant tumors in guinea pigs.
Fossel ET; Dvorak HF; Carr JM; McDonagh J
Eur J Cancer; 1990 Jan; 26(1):29-32. PubMed ID: 2138474
[TBL] [Abstract][Full Text] [Related]
16. [Tumor detection in serum by NMR spectrometry. A critical evaluation of the so-called Fossel test].
Schalk KP; Rüterjans H; Kaltwasser JP; Said l-Hadj H; Staffenberger L
Onkologie; 1989 Aug; 12 Suppl 1():5-8. PubMed ID: 2685697
[TBL] [Abstract][Full Text] [Related]
17. Proton magnetic resonance spectroscopy of fractionated plasma lipoproteins and reconstituted plasma from healthy subjects and patients with cancer.
Engan T; Bjerve KS; Høe AL; Krane J
Scand J Clin Lab Invest; 1992 Sep; 52(5):393-408. PubMed ID: 1514018
[TBL] [Abstract][Full Text] [Related]
18. Study of the ability of proton nuclear magnetic resonance spectroscopy of human plasma to differentiate between controls and breast cancer patients.
Moreno A; Escrich E; Prats M; Benito N; Alonso J; Arús C
Oncology; 1993; 50(2):110-5. PubMed ID: 8383828
[TBL] [Abstract][Full Text] [Related]
19. NMR spectroscopy evaluation of plasma "oncolipids" in head and neck cancer.
Scher RL; Ropka ME; Neal DA; Berr S; Trouard T; Deutsch B; Cantrell RW; Levine PA
Otolaryngol Head Neck Surg; 1990 Jan; 102(1):34-40. PubMed ID: 2106116
[TBL] [Abstract][Full Text] [Related]
20. Proton nuclear magnetic resonance lineshape studies on human blood plasma lipids from newborn infants, healthy adults, and adults with tumors.
Hiltunen Y; Ala-Korpela M; Jokisaari J; Eskelinen S; Kiviniitty K
Magn Reson Med; 1992 Jul; 26(1):89-99. PubMed ID: 1625571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
